14:21 uur 10-11-2021

Exscientia rapporteert financiële resultaten derde kwartaal 2021 op 17 november 2021

Bedrijf organiseert conference call en webcast op 18 november 2021 om 13:30 uur GMT / 8:30 uur ET

OXFORD, Engeland–(BUSINESS WIRE)– Exscientia (Nasdaq: EXAI), een AI-gedreven farmaceutisch bedrijf dat zich inzet voor het ontdekken, ontwerpen en ontwikkelen van de best mogelijke medicijnen op de snelste en meest effectieve manier, zal financiële resultaten rapporteren voor het derde kwartaal dat eindigde 30 september 2021, op woensdag 17 november 2021 na sluiting van de Amerikaanse markt. Na de aankondiging zal het bedrijf om 13.30 uur een telefonische vergadering en webcast houden. GMT / 8:30 a.m. ET op donderdag 18 november 2021, om aanvullende details te geven over de verschillende bedrijfsmodellen die ten grondslag liggen aan de pijplijn van het bedrijf met meer dan 25 programma’s.

Exscientia to Report Third Quarter 2021 Financial Results on November 17, 2021

Company to host conference call and webcast on November 18, 2021 at 1:30 p.m. GMT / 8:30 a.m. ET

OXFORD, England–(BUSINESS WIRE)– Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, will report financial results for the third quarter ended September 30, 2021, on Wednesday, November 17, 2021 after U.S. market close. Following the announcement, the Company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. ET on Thursday, November 18, 2021, to provide additional detail on the different business models underlying the company’s pipeline of more than 25 programmes.

A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (760) 294 1674 (U.S.), +44 203 059 5869 (U.K.), +44 203 059 8128 (International) and mentioning Exscientia. A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.

Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston and Osaka. For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Contacts

Investors:
Sara Sherman

investors@exscientia.ai

Media:
Amanda Galgay

media@exscientia.ai

Check out our twitter: @NewsNovumpr